Wire · opportunities
Sellas marks 9-month survival in ph. 3 leukemia vaccine study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
Sellas Life Sciences' leukemia vaccine galinpepimut-S (GPS) demonstrated a significant survival benefit in a phase 3 trial for acute myeloid leukemia, achieving a median overall survival of 24 months versus less than 15 months for standard therapy. The company plans to begin an accelerated FDA filing following successful trial results.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clearer path to FDA approval in leukemia immunotherapy after a vaccine showed robust survival gains. This pushes you to accelerate FDA filings and explore combos with checkpoint inhibitors to claim early market advantage.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics